Oregon Lithoprint, Inc.; Analysis To Aid Public Comment, 11529-11532 [2018-05252]
Download as PDF
Federal Register / Vol. 83, No. 51 / Thursday, March 15, 2018 / Notices
period will become part of the public
record. After 30 days, the Commission
will again review the Consent
Agreement and the comments received,
and will decide whether it should
withdraw from the Consent Agreement,
modify it, or make final the Decision
and Order (‘‘Order’’).
II. The Parties
A. AMGH
AMGH is wholly owned by KKR
North America Fund XI (AMG) LLC. It
is likely the largest provider of air
ambulance services in the United States
with 270 operating locations in 38
states. AMGH operates as Hawaii Life
Flight in Hawaii.
B. AMR
AMR is a wholly-owned subsidiary of
Envision Healthcare and is the largest
national ground ambulance provider in
the United States, but also provides air
ambulance services in several locations.
In Hawaii, it provides both ground
ambulance services and inter-facility air
ambulance transport services. To
provide inter-facility air ambulance
transport services, AMR partners with
LifeTeam, an air ambulance provider
located in the Midwest, which has the
necessary FAA licenses and
certifications, and provides the pilots
and maintenance for the fixed-wing
aircraft. AMR handles the marketing,
medical personnel, and billing for the
services provided.
sradovich on DSK3GMQ082PROD with NOTICES
III. The Proposed Acquisition
Under an agreement executed on
August 7, 2017, AMGH will acquire 100
percent of the voting stock of AMR in
a deal valued at approximately $2.4
billion.
The Commission’s Complaint alleges
that the Acquisition, if consummated
would violate Section 7 of the Clayton
Act, as amended, 15 U.S.C. 18, and
Section 5 of the FTC Act, as amended,
15 U.S.C. 45, by substantially lessening
competition for the provision of interfacility air ambulance transport services
in Hawaii.
IV. The Relevant Market and Structure
of the Markets
The Commission’s Complaint alleges
that the relevant product market in
which to analyze the Acquisition is the
provision of inter-facility air ambulance
transport services. These services
consist of air ambulance services that
transfer patients between medical
facilities on different islands, including
from medical facilities with low acuity
or limited patient treatment capabilities
to those that can provide the
appropriate medical and surgical care.
VerDate Sep<11>2014
17:34 Mar 14, 2018
Jkt 244001
The Commission’s Complaint alleges
that the relevant geographic market in
which to analyze the effects of the
Acquisition is the State of Hawaii.
The Commission’s Complaint alleges
that the Acquisition will increase
concentration in an already highly
concentrated market. AMGH and AMR
are the only two providers of interfacility air ambulance transport services
in Hawaii.
V. Effects of the Transaction
According to the Commission, the
effect of the Acquisition, if
consummated, may be substantially to
lessen competition and tend to create a
monopoly in inter-facility air ambulance
transport services, and increase the
likelihood of the unilateral exercise of
market power. The Acquisition would
increase the likelihood that consumers,
third-party payers, or government health
care providers would be forced to pay
higher prices or experience degradation
in service or quality.
VI. Entry Conditions
The Commission’s Complaint alleges
that entry into the relevant market
would not be timely, likely, or sufficient
to deter or counteract the
anticompetitive effects of the
Acquisition. The primary barrier to
entry is the lack of sufficient volume of
referrals and payments from third party
payers to justify the economic risk of
new entry, even if the parties imposed
a small but significant non-transitory
increase in price (SSNIP).
VII. The Proposed Consent Agreement
The proposed Consent Agreement
remedies the anticompetitive concerns
raised by the Acquisition by requiring
AMR to sell its inter-facility air
ambulance transport services business,
including the assets that support that
business, to AIRMD, LLC, dba LifeTeam.
LifeTeam is a large, established
company with experience in the
industry. It is also the current operator
of the FAA certified aircraft used by
AMR for inter-facility air ambulance
transport services in Hawaii, and thus
very familiar with AMR’s assets and
operations in Hawaii. Under the
proposed Consent Agreement, AMR will
divest to LifeTeam the four-fixed wing
aircraft it uses to fly patients interisland, support LifeTeam’s application
for a Certificate of Need with the State
of Hawaii to operate ground
ambulances, and offer LifeTeam the
option to purchase up to four ground
ambulances from AMR. LifeTeam would
use the ground ambulances to support
its air ambulance transport service to
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
11529
transfer patients to and from medical
facilities and the aircraft it operates.
The proposed Consent Agreement
also contains an Order to Maintain
Assets that will issue at the time the
proposed Consent Agreement is
accepted for public comment. The Order
to Maintain Assets requires
Respondents to operate and maintain
the divestiture assets in the normal
course of business through the date that
the Respondents complete divestiture of
the assets, thereby maintaining the
economic viability, marketability, and
competitiveness of the assets. The Order
to Maintain Assets also authorizes the
Commission to appoint an independent
third party as a monitor to oversee the
Respondents’ compliance with the
requirements of the proposed Consent
Agreement.
The purpose of this analysis is to
facilitate public comment on the
proposed Consent agreement, and the
Commission does not intend this
analysis to constitute an official
interpretation of the proposed Consent
Agreement or to modify its terms in any
way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018–05251 Filed 3–14–18; 8:45 am]
BILLING CODE 6750–01–P
FEDERAL TRADE COMMISSION
[File No. 161 0230]
Oregon Lithoprint, Inc.; Analysis To
Aid Public Comment
Federal Trade Commission.
Proposed consent agreement.
AGENCY:
ACTION:
The consent agreement in this
matter settles alleged violations of
federal law prohibiting unfair methods
of competition. The attached Analysis to
Aid Public Comment describes both the
allegations in the complaint and the
terms of the consent order—embodied
in the consent agreement—that would
settle these allegations.
DATES: Comments must be received on
or before April 8, 2018.
ADDRESSES: Interested parties may file a
comment online or on paper, by
following the instructions in the
Request for Comment part of the
SUPPLEMENTARY INFORMATION section
below. Write: ‘‘In the Matter of
Oregon Lithoprint, Inc., File No. 161
0230’’ on your comment, and file your
comment online at https://
ftcpublic.commentworks.com/ftc/oregon
lithoprintconsent by following the
instructions on the web-based form. If
SUMMARY:
E:\FR\FM\15MRN1.SGM
15MRN1
sradovich on DSK3GMQ082PROD with NOTICES
11530
Federal Register / Vol. 83, No. 51 / Thursday, March 15, 2018 / Notices
you prefer to file your comment on
paper, write ‘‘In the Matter of Oregon
Lithoprint, Inc., File No. 161 0230’’ on
your comment and on the envelope, and
mail your comment to the following
address: Federal Trade Commission,
Office of the Secretary, 600
Pennsylvania Avenue NW, Suite CC–
5610 (Annex D), Washington, DC 20580,
or deliver your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW,
5th Floor, Suite 5610 (Annex D),
Washington, DC 20024.
FOR FURTHER INFORMATION CONTACT:
Michael Turner (202–326–3619), Bureau
of Competition, 600 Pennsylvania
Avenue NW, Washington, DC 20580.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 6(f) of the Federal Trade
Commission Act, 15 U.S.C. 46(f), and
FTC Rule 2.34, 16 CFR 2.34, notice is
hereby given that the above-captioned
consent agreement containing a consent
order to cease and desist, having been
filed with and accepted, subject to final
approval, by the Commission, has been
placed on the public record for a period
of thirty (30) days. The following
Analysis to Aid Public Comment
describes the terms of the consent
agreement, and the allegations in the
complaint. An electronic copy of the
full text of the consent agreement
package can be obtained from the FTC
Home Page (for March 9, 2018), on the
World Wide Web, at https://
www.ftc.gov/news-events/commissionactions.
You can file a comment online or on
paper. For the Commission to consider
your comment, we must receive it on or
before April 8, 2018. Write ‘‘In the
Matter of Oregon Lithoprint, Inc., File
No. 161 0230’’ on your comment. Your
comment—including your name and
your state—will be placed on the public
record of this proceeding, including, to
the extent practicable, on the public
Commission website, at https://
www.ftc.gov/policy/public-comments.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online. To make sure that the
Commission considers your online
comment, you must file it at https://
ftcpublic.commentworks.com/ftc/oregon
lithoprintconsent by following the
instructions on the web-based form. If
this Notice appears at https://
www.regulations.gov/#!home, you also
may file a comment through that
website.
If you prefer to file your comment on
paper, write ‘‘In the Matter of Oregon
VerDate Sep<11>2014
17:34 Mar 14, 2018
Jkt 244001
Lithoprint, Inc., File No. 161 0230’’ on
your comment and on the envelope, and
mail your comment to the following
address: Federal Trade Commission,
Office of the Secretary, 600
Pennsylvania Avenue NW, Suite CC–
5610 (Annex D), Washington, DC 20580,
or deliver your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW,
5th Floor, Suite 5610 (Annex D),
Washington, DC 20024. If possible,
submit your paper comment to the
Commission by courier or overnight
service.
Because your comment will be placed
on the publicly accessible FTC website
at https://www.ftc.gov, you are solely
responsible for making sure that your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which . . . is privileged or
confidential’’—as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted on the public FTC
website—as legally required by FTC
Rule 4.9(b)—we cannot redact or
remove your comment from the FTC
website, unless you submit a
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
confidentiality request that meets the
requirements for such treatment under
FTC Rule 4.9(c), and the General
Counsel grants that request.
Visit the FTC website at https://
www.ftc.gov to read this Notice and the
news release describing it. The FTC Act
and other laws that the Commission
administers permit the collection of
public comments to consider and use in
this proceeding, as appropriate. The
Commission will consider all timely
and responsive public comments that it
receives on or before April 8, 2018. For
information on the Commission’s
privacy policy, including routine uses
permitted by the Privacy Act, see
https://www.ftc.gov/site-information/
privacy-policy.
Analysis of Agreement Containing
Consent Orders To Aid Public Comment
The Federal Trade Commission
(‘‘Commission’’) has accepted, subject to
final approval, an agreement containing
consent order (‘‘Consent Agreement’’)
from Oregon Lithoprint Inc. (‘‘OLI’’).
The Commission’s Complaint alleges
that OLI violated Section 5 of the
Federal Trade Commission Act, as
amended, 15 U.S.C. 45, by inviting a
competitor in the publication of
foreclosure notices to divide clients by
geographic market.
Under the terms of the proposed
Consent Agreement, OLI is required to
cease and desist from communicating
with its competitors about the
placement of foreclosure notices. It is
also barred from entering into,
participating in, inviting, or soliciting
an agreement with any competitor to
divide markets or to allocate customers.
The Consent Agreement has been
placed on the public record for 30 days
for receipt of comments from interested
members of the public. Comments
received during this period will become
part of the public record. After 30 days,
the Commission will review the Consent
Agreement again and the comments
received, and will decide whether it
should withdraw from the Consent
Agreement or make final the
accompanying Decision and Order
(‘‘Proposed Order’’).
The purpose of this Analysis to Aid
Public Comment is to invite and
facilitate public comment. It is not
intended to constitute an official
interpretation of the proposed Consent
Agreement and the accompanying
Proposed Order or in any way to modify
their terms.
I. The Complaint
The allegations of the Complaint are
summarized below:
E:\FR\FM\15MRN1.SGM
15MRN1
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 51 / Thursday, March 15, 2018 / Notices
OLI owns the News-Register, a twiceweekly community newspaper based in
Yamhill, Oregon. Among other things,
the News-Register charges clients to
publish a type of legal notice known as
a foreclosure notice. Under Oregon law,
parties foreclosing on real property must
place a notice of foreclosure in a
qualifying newspaper in the county
within which the property is located.
The News-Register’s only competitor
in Yamhill County is The Newberg
Graphic, a weekly community
newspaper. The Newberg Graphic also
publishes foreclosure notices, and it
charges considerably less than the
News-Register for the service. The
News-Register has more subscribers and
a wider circulation within Yamhill
County than The Newberg Graphic.
In August 2016, the publisher of the
News-Register learned that a client
intended to place foreclosure notices
only in The Newberg Graphic from that
point on because The Newberg Graphic
was less expensive than the NewsRegister. In response, on August 29,
2016, the publisher emailed a manager
at the parent company of The Newberg
Graphic and explained the publisher’s
view that, under state law, foreclosure
notices should be placed in the
newspaper with the largest circulation
in the area that the property is located.
The publisher concluded his email by
inviting the competitor to join the
News-Register in instructing mutual
clients that they should place
foreclosure notices in the newspaper
dominant in the area of the foreclosed
property. The parent company of the
The Newberg Graphic rejected the
invitation and reported it to the Federal
Trade Commission.
Several months later, in October 2016,
the publisher of the News-Register
emailed the competitor again to state
that the News-Register had told a client
to use The Newberg Graphic because the
property in question was located in its
area, and that the client was in fact
going to use The Newberg Graphic to
publish the notice. He ended the email
stating ‘‘[i]t is probably too much to
expect that others would do likewise.’’
The parent company of the The
Newberg Graphic interpreted this
second email as another invitation to
collude, rejected the invitation, and
reported it to the Federal Trade
Commission.
II. Analysis
OLI’s August 29, 2016, email to its
competitor is an explicit attempt to
arrange an agreement between the two
companies to divide foreclosure notices
by geography. It is an invitation to
collude. The October 2016 email is also
VerDate Sep<11>2014
17:34 Mar 14, 2018
Jkt 244001
an invitation to collude: OLI proposed
a market allocation scheme and
expressed a hope that its competitor
would join that conduct. The
Commission has long held that
invitations to collude violate Section 5
of the FTC Act.
In a 2015 statement, the Commission
explained that unfair methods of
competition under Section 5 ‘‘must
cause, or be likely to cause, harm to
competition or the competitive process,
taking into account any associated
cognizable efficiencies and business
justifications.’’ 1 Potential violations are
evaluated under a ‘‘framework similar to
the rule of reason.’’ 2 Competitive effects
analysis under the rule of reason
depends upon the nature of the conduct
that is under review.3
An invitation to collude is
‘‘potentially harmful and . . . serves no
legitimate business purpose.’’ 4 For this
reason, the Commission treats such
conduct as ‘‘inherently suspect’’ (that is,
presumptively anticompetitive).5
Accordingly, an invitation to collude
can be condemned under Section 5
without a showing that the respondent
possesses market power.6
The Commission has long held that an
invitation to collude violates Section 5
of the FTC Act even where there is no
proof that the competitor accepted the
1 Fed. Trade Comm’n, Statement of Enforcement
Principles Regarding ‘‘Unfair Methods of
Competition’’ Under Section 5 of the FTC Act (Aug.
13, 2015) (Section 5 Unfair Methods of Competition
Policy Statement), available at https://www.ftc.gov/
system/files/documents/public_statements/735201/
150813section5enforcement.pdf. Acting Chairman
Ohlhausen dissented from the issuance of the
Section 5 Unfair Methods of Competition Policy
Statement. See https://www.ftc.gov/publicstatements/2015/08/dissenting-statementcommissioner-ohlhausen-ftc-act-section-5-policy.
2 Section 5 Unfair Methods of Competition Policy
Statement.
3 See, e.g., California Dental Ass’n v. FTC, 526
U.S. 756, 781 (1999) (‘‘What is required . . . is an
inquiry meet for the case, looking to the
circumstances, details, and logic of a restraint.’’).
4 In re Valassis Commc’ns., Inc., 141 F.T.C. 247,
283 (2006) (Analysis of Agreement Containing
Consent Order to Aid Public Comment); see also
Address by FTC Chairwoman Edith Ramirez,
Section 5 Enforcement Principles, George
Washington University Law School at 5 (Aug. 13,
2015), available at https://www.ftc.gov/system/files/
documents/public_statements/735411/
150813section5speech.pdf.
5 See, e.g., In re North Carolina Bd. of Dental
Examiners, 152 F.T.C. 640, 668 (2011) (noting that
conduct is inherently suspect if it can be
‘‘reasonably characterized as ‘giv[ing] rise to an
intuitively obviously inference of anticompetitive
effect.’ ’’ (citation omitted)).
6 See, e.g., In re Realcomp II, Ltd., 148 F.T.C.
___, No. 9320, 2009 FTC LEXIS 250 at *51 (Oct. 30,
2009) (Comm’n Op.) (explaining that if conduct is
‘‘inherently suspect’’ in nature, and there are no
cognizable procompetitive justifications, the
Commission can condemn it ‘‘without proof of
market power or actual effects’’).
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
11531
invitation 7 This is for several reasons.
First, unaccepted solicitations may
facilitate coordination between
competitors because they reveal
information about the solicitor’s
intentions or preferences. Second, it can
be difficult to discern whether a
competitor has accepted a solicitation.
Third, finding a violation may deter
conduct that has no legitimate business
purpose.8
III. The Proposed Consent Order
The Proposed Order contains the
following substantive provisions:
Section II, Paragraph A of the
Proposed Order enjoins OLI from
entering or attempting to enter any
agreement to refuse to publish legal
notices or allocate customers for the
publication of legal notices.
Section II, Paragraph B prohibits OLI
from publically or privately
communicating with a competitor that
the competitor should advice customers
to place foreclosure notices in the
newspaper with the widest circulation
in the area in which the property is
located, or refuse to publish notices for
properties located in a competitor’s
primary distribution area.
Section II, Paragraph C, contains three
provisos. The first allows OLI to
communicate with any governmental
body regarding the proper interpretation
of state law related to legal notices. The
second allows OLI to participate with
any effort of the Oregon newspaper
association to lobby any governmental
body regarding legal notices. The third
allows OLI to disseminate information
regarding legal notices to the public.
Sections III–VI of the Proposed Order
impose certain standard reporting and
compliance requirements on OLI.
The Proposed Order will expire in 10
years.
7 See, e.g., In re Valassis Commc’ns, Inc., 141
F.T.C. 247 (2006); In re Stone Container, 125 F.T.C.
853 (1998); In re Precision Moulding, 122 F.T.C. 104
(1996). See also In re McWane, Inc., Docket No.
9351, Opinion of the Commission on Motions for
Summary Decision at 20–21 (F.T.C. Aug. 9, 2012)
(‘‘an invitation to collude is ‘the quintessential
example of the kind of conduct that should be . . .
challenged as a violation of Section 5’ ’’) (citing the
Statement of Chairman Liebowitz and
Commissioners Kovacic and Rosch, In re U-Haul
Int’l, Inc., 150 F.T.C. 1, 53 (2010)). This conclusion
has been endorsed by leading antitrust scholars. See
P. Areeda & H. Hovenkamp, VI ANTITRUST LAW
¶ 1419 (2003); Stephen Calkins, Counterpoint: The
Legal Foundation of the Commission’s Use of
Section 5 to Challenge Invitations to Collude is
Secure, ANTITRUST Spring 2000, at 69. In a case
brought under a state’s version of Section 5, the
First Circuit expressed support for the
Commission’s application of Section 5 to
invitations to collude. Liu v. Amerco, 677 F.3d 489
(1st Cir. 2012).
8 In re Valassis Comm’c, Inc., 141 F.T.C. 247, 283
(2006) (Analysis of Agreement Containing Consent
Order to Aid Public Comment).
E:\FR\FM\15MRN1.SGM
15MRN1
11532
Federal Register / Vol. 83, No. 51 / Thursday, March 15, 2018 / Notices
The purpose of this analysis is to
facilitate public comment on the
proposed Consent agreement, and the
Commission does not intend this
analysis to constitute an official
interpretation of the proposed Consent
Agreement or to modify its terms in any
way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018–05252 Filed 3–14–18; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2016–0094]
Final Revised Vaccine Information
Materials for MMR (Measles, Mumps,
and Rubella) and MMRV (Measles,
Mumps, Rubella, and Varicella)
Vaccines
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA),
CDC must develop vaccine information
materials that all health care providers
are required to give to patients/parents
prior to administration of specific
vaccines. On October 18, 2016, CDC
published a notice in the Federal
Register seeking public comments on
proposed updated vaccine information
materials for MMR vaccine and MMRV
vaccine. Following review of comments
submitted and consultation as required
under the law, CDC has finalized the
materials. Copies of the final vaccine
information materials for MMR and
MMRV vaccine are available to
download from https://www.cdc.gov/
vaccines/hcp/vis/ or https://
www.regulations.gov (see Docket
Number CDC–2016–0094).
DATES: Beginning no later than June 1,
2018, each health care provider who
administers MMR or MMRV vaccine to
any child or adult in the United States
shall provide copies of the relevant
vaccine information materials
referenced in this notice, dated February
12, 2018, in conformance with the
February 23, 2018 CDC Instructions for
the Use of Vaccine Information
Statements prior to providing such
vaccinations.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon (msj1@
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:34 Mar 14, 2018
Jkt 244001
cdc.gov), National Center for
Immunization and Respiratory Diseases,
Centers for Disease Control and
Prevention, Mailstop A–19, 1600 Clifton
Road NE, Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella, and poliomyelitis vaccines.
Since April 15, 1992, any health care
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Since then, the following vaccines have
been added to the National Vaccine
Injury Compensation Program, requiring
use of vaccine information materials for
them as well: Hepatitis B, Haemophilus
influenzae type b (Hib), varicella
(chickenpox), pneumococcal conjugate,
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
rotavirus, hepatitis A, meningococcal,
human papillomavirus (HPV), and
seasonal influenza vaccines.
Instructions for use of the vaccine
information materials are found on the
CDC website at: https://www.cdc.gov/
vaccines/hcp/vis/.
Revised Vaccine Information Materials
The vaccine information materials
referenced in this notice were
developed in consultation with the
Advisory Commission on Childhood
Vaccines, the Food and Drug
Administration, and parent and
healthcare provider organizations.
Following consultation and review of
comments submitted, the vaccine
information materials covering MMR
and MMRV vaccines have been
finalized and are available to download
from https://www.cdc.gov/vaccines/hcp/
vis/ or https://
www.regulations.gov (see Docket
Number CDC–2016–0094). The Vaccine
Information Statements (VISs) are
‘‘MMR Vaccine (Measles, Mumps, and
Rubella): What You Need to Know’’ and
‘‘MMRV Vaccine (Measles, Mumps,
Rubella, and Varicella): What You Need
to Know,’’ publication date February 12,
2018.
With publication of this notice, by
June 1, 2018, all health care providers
must discontinue use of the previous
editions and provide copies of these
updated vaccine information materials
prior to immunization in conformance
with CDC’s February 23, 2018
Instructions for the Use of Vaccine
Information Statements.
Dated: March 12, 2018.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2018–05299 Filed 3–14–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–FY–1072; Docket No. CDC–2018–
0020]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
SUMMARY:
E:\FR\FM\15MRN1.SGM
15MRN1
Agencies
[Federal Register Volume 83, Number 51 (Thursday, March 15, 2018)]
[Notices]
[Pages 11529-11532]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05252]
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. 161 0230]
Oregon Lithoprint, Inc.; Analysis To Aid Public Comment
AGENCY: Federal Trade Commission.
ACTION: Proposed consent agreement.
-----------------------------------------------------------------------
SUMMARY: The consent agreement in this matter settles alleged
violations of federal law prohibiting unfair methods of competition.
The attached Analysis to Aid Public Comment describes both the
allegations in the complaint and the terms of the consent order--
embodied in the consent agreement--that would settle these allegations.
DATES: Comments must be received on or before April 8, 2018.
ADDRESSES: Interested parties may file a comment online or on paper, by
following the instructions in the Request for Comment part of the
SUPPLEMENTARY INFORMATION section below. Write: ``In the Matter of
Oregon Lithoprint, Inc., File No. 161 0230'' on your comment, and file
your comment online at https://ftcpublic.commentworks.com/ftc/oregonlithoprintconsent by following the instructions on the web-based
form. If
[[Page 11530]]
you prefer to file your comment on paper, write ``In the Matter of
Oregon Lithoprint, Inc., File No. 161 0230'' on your comment and on the
envelope, and mail your comment to the following address: Federal Trade
Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite
CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the
following address: Federal Trade Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex
D), Washington, DC 20024.
FOR FURTHER INFORMATION CONTACT: Michael Turner (202-326-3619), Bureau
of Competition, 600 Pennsylvania Avenue NW, Washington, DC 20580.
SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal
Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34,
notice is hereby given that the above-captioned consent agreement
containing a consent order to cease and desist, having been filed with
and accepted, subject to final approval, by the Commission, has been
placed on the public record for a period of thirty (30) days. The
following Analysis to Aid Public Comment describes the terms of the
consent agreement, and the allegations in the complaint. An electronic
copy of the full text of the consent agreement package can be obtained
from the FTC Home Page (for March 9, 2018), on the World Wide Web, at
https://www.ftc.gov/news-events/commission-actions.
You can file a comment online or on paper. For the Commission to
consider your comment, we must receive it on or before April 8, 2018.
Write ``In the Matter of Oregon Lithoprint, Inc., File No. 161 0230''
on your comment. Your comment--including your name and your state--will
be placed on the public record of this proceeding, including, to the
extent practicable, on the public Commission website, at https://www.ftc.gov/policy/public-comments.
Postal mail addressed to the Commission is subject to delay due to
heightened security screening. As a result, we encourage you to submit
your comments online. To make sure that the Commission considers your
online comment, you must file it at https://ftcpublic.commentworks.com/ftc/oregonlithoprintconsent by following the instructions on the web-
based form. If this Notice appears at https://www.regulations.gov/#!home, you also may file a comment through that website.
If you prefer to file your comment on paper, write ``In the Matter
of Oregon Lithoprint, Inc., File No. 161 0230'' on your comment and on
the envelope, and mail your comment to the following address: Federal
Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW,
Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment
to the following address: Federal Trade Commission, Office of the
Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite
5610 (Annex D), Washington, DC 20024. If possible, submit your paper
comment to the Commission by courier or overnight service.
Because your comment will be placed on the publicly accessible FTC
website at https://www.ftc.gov, you are solely responsible for making
sure that your comment does not include any sensitive or confidential
information. In particular, your comment should not include any
sensitive personal information, such as your or anyone else's Social
Security number; date of birth; driver's license number or other state
identification number, or foreign country equivalent; passport number;
financial account number; or credit or debit card number. You are also
solely responsible for making sure that your comment does not include
any sensitive health information, such as medical records or other
individually identifiable health information. In addition, your comment
should not include any ``trade secret or any commercial or financial
information which . . . is privileged or confidential''--as provided by
Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2),
16 CFR 4.10(a)(2)--including in particular competitively sensitive
information such as costs, sales statistics, inventories, formulas,
patterns, devices, manufacturing processes, or customer names.
Comments containing material for which confidential treatment is
requested must be filed in paper form, must be clearly labeled
``Confidential,'' and must comply with FTC Rule 4.9(c). In particular,
the written request for confidential treatment that accompanies the
comment must include the factual and legal basis for the request, and
must identify the specific portions of the comment to be withheld from
the public record. See FTC Rule 4.9(c). Your comment will be kept
confidential only if the General Counsel grants your request in
accordance with the law and the public interest. Once your comment has
been posted on the public FTC website--as legally required by FTC Rule
4.9(b)--we cannot redact or remove your comment from the FTC website,
unless you submit a confidentiality request that meets the requirements
for such treatment under FTC Rule 4.9(c), and the General Counsel
grants that request.
Visit the FTC website at https://www.ftc.gov to read this Notice and
the news release describing it. The FTC Act and other laws that the
Commission administers permit the collection of public comments to
consider and use in this proceeding, as appropriate. The Commission
will consider all timely and responsive public comments that it
receives on or before April 8, 2018. For information on the
Commission's privacy policy, including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/site-information/privacy-policy.
Analysis of Agreement Containing Consent Orders To Aid Public Comment
The Federal Trade Commission (``Commission'') has accepted, subject
to final approval, an agreement containing consent order (``Consent
Agreement'') from Oregon Lithoprint Inc. (``OLI''). The Commission's
Complaint alleges that OLI violated Section 5 of the Federal Trade
Commission Act, as amended, 15 U.S.C. 45, by inviting a competitor in
the publication of foreclosure notices to divide clients by geographic
market.
Under the terms of the proposed Consent Agreement, OLI is required
to cease and desist from communicating with its competitors about the
placement of foreclosure notices. It is also barred from entering into,
participating in, inviting, or soliciting an agreement with any
competitor to divide markets or to allocate customers.
The Consent Agreement has been placed on the public record for 30
days for receipt of comments from interested members of the public.
Comments received during this period will become part of the public
record. After 30 days, the Commission will review the Consent Agreement
again and the comments received, and will decide whether it should
withdraw from the Consent Agreement or make final the accompanying
Decision and Order (``Proposed Order'').
The purpose of this Analysis to Aid Public Comment is to invite and
facilitate public comment. It is not intended to constitute an official
interpretation of the proposed Consent Agreement and the accompanying
Proposed Order or in any way to modify their terms.
I. The Complaint
The allegations of the Complaint are summarized below:
[[Page 11531]]
OLI owns the News-Register, a twice-weekly community newspaper
based in Yamhill, Oregon. Among other things, the News-Register charges
clients to publish a type of legal notice known as a foreclosure
notice. Under Oregon law, parties foreclosing on real property must
place a notice of foreclosure in a qualifying newspaper in the county
within which the property is located.
The News-Register's only competitor in Yamhill County is The
Newberg Graphic, a weekly community newspaper. The Newberg Graphic also
publishes foreclosure notices, and it charges considerably less than
the News-Register for the service. The News-Register has more
subscribers and a wider circulation within Yamhill County than The
Newberg Graphic.
In August 2016, the publisher of the News-Register learned that a
client intended to place foreclosure notices only in The Newberg
Graphic from that point on because The Newberg Graphic was less
expensive than the News-Register. In response, on August 29, 2016, the
publisher emailed a manager at the parent company of The Newberg
Graphic and explained the publisher's view that, under state law,
foreclosure notices should be placed in the newspaper with the largest
circulation in the area that the property is located. The publisher
concluded his email by inviting the competitor to join the News-
Register in instructing mutual clients that they should place
foreclosure notices in the newspaper dominant in the area of the
foreclosed property. The parent company of the The Newberg Graphic
rejected the invitation and reported it to the Federal Trade
Commission.
Several months later, in October 2016, the publisher of the News-
Register emailed the competitor again to state that the News-Register
had told a client to use The Newberg Graphic because the property in
question was located in its area, and that the client was in fact going
to use The Newberg Graphic to publish the notice. He ended the email
stating ``[i]t is probably too much to expect that others would do
likewise.''
The parent company of the The Newberg Graphic interpreted this
second email as another invitation to collude, rejected the invitation,
and reported it to the Federal Trade Commission.
II. Analysis
OLI's August 29, 2016, email to its competitor is an explicit
attempt to arrange an agreement between the two companies to divide
foreclosure notices by geography. It is an invitation to collude. The
October 2016 email is also an invitation to collude: OLI proposed a
market allocation scheme and expressed a hope that its competitor would
join that conduct. The Commission has long held that invitations to
collude violate Section 5 of the FTC Act.
In a 2015 statement, the Commission explained that unfair methods
of competition under Section 5 ``must cause, or be likely to cause,
harm to competition or the competitive process, taking into account any
associated cognizable efficiencies and business justifications.'' \1\
Potential violations are evaluated under a ``framework similar to the
rule of reason.'' \2\ Competitive effects analysis under the rule of
reason depends upon the nature of the conduct that is under review.\3\
---------------------------------------------------------------------------
\1\ Fed. Trade Comm'n, Statement of Enforcement Principles
Regarding ``Unfair Methods of Competition'' Under Section 5 of the
FTC Act (Aug. 13, 2015) (Section 5 Unfair Methods of Competition
Policy Statement), available at https://www.ftc.gov/system/files/documents/public_statements/735201/150813section5enforcement.pdf.
Acting Chairman Ohlhausen dissented from the issuance of the Section
5 Unfair Methods of Competition Policy Statement. See https://www.ftc.gov/public-statements/2015/08/dissenting-statement-commissioner-ohlhausen-ftc-act-section-5-policy.
\2\ Section 5 Unfair Methods of Competition Policy Statement.
\3\ See, e.g., California Dental Ass'n v. FTC, 526 U.S. 756, 781
(1999) (``What is required . . . is an inquiry meet for the case,
looking to the circumstances, details, and logic of a restraint.'').
---------------------------------------------------------------------------
An invitation to collude is ``potentially harmful and . . . serves
no legitimate business purpose.'' \4\ For this reason, the Commission
treats such conduct as ``inherently suspect'' (that is, presumptively
anticompetitive).\5\ Accordingly, an invitation to collude can be
condemned under Section 5 without a showing that the respondent
possesses market power.\6\
---------------------------------------------------------------------------
\4\ In re Valassis Commc'ns., Inc., 141 F.T.C. 247, 283 (2006)
(Analysis of Agreement Containing Consent Order to Aid Public
Comment); see also Address by FTC Chairwoman Edith Ramirez, Section
5 Enforcement Principles, George Washington University Law School at
5 (Aug. 13, 2015), available at https://www.ftc.gov/system/files/documents/public_statements/735411/150813section5speech.pdf.
\5\ See, e.g., In re North Carolina Bd. of Dental Examiners, 152
F.T.C. 640, 668 (2011) (noting that conduct is inherently suspect if
it can be ``reasonably characterized as `giv[ing] rise to an
intuitively obviously inference of anticompetitive effect.' ''
(citation omitted)).
\6\ See, e.g., In re Realcomp II, Ltd., 148 F.T.C. ___, No.
9320, 2009 FTC LEXIS 250 at *51 (Oct. 30, 2009) (Comm'n Op.)
(explaining that if conduct is ``inherently suspect'' in nature, and
there are no cognizable procompetitive justifications, the
Commission can condemn it ``without proof of market power or actual
effects'').
---------------------------------------------------------------------------
The Commission has long held that an invitation to collude violates
Section 5 of the FTC Act even where there is no proof that the
competitor accepted the invitation \7\ This is for several reasons.
First, unaccepted solicitations may facilitate coordination between
competitors because they reveal information about the solicitor's
intentions or preferences. Second, it can be difficult to discern
whether a competitor has accepted a solicitation. Third, finding a
violation may deter conduct that has no legitimate business purpose.\8\
---------------------------------------------------------------------------
\7\ See, e.g., In re Valassis Commc'ns, Inc., 141 F.T.C. 247
(2006); In re Stone Container, 125 F.T.C. 853 (1998); In re
Precision Moulding, 122 F.T.C. 104 (1996). See also In re McWane,
Inc., Docket No. 9351, Opinion of the Commission on Motions for
Summary Decision at 20-21 (F.T.C. Aug. 9, 2012) (``an invitation to
collude is `the quintessential example of the kind of conduct that
should be . . . challenged as a violation of Section 5' '') (citing
the Statement of Chairman Liebowitz and Commissioners Kovacic and
Rosch, In re U-Haul Int'l, Inc., 150 F.T.C. 1, 53 (2010)). This
conclusion has been endorsed by leading antitrust scholars. See P.
Areeda & H. Hovenkamp, VI ANTITRUST LAW ] 1419 (2003); Stephen
Calkins, Counterpoint: The Legal Foundation of the Commission's Use
of Section 5 to Challenge Invitations to Collude is Secure,
ANTITRUST Spring 2000, at 69. In a case brought under a state's
version of Section 5, the First Circuit expressed support for the
Commission's application of Section 5 to invitations to collude. Liu
v. Amerco, 677 F.3d 489 (1st Cir. 2012).
\8\ In re Valassis Comm'c, Inc., 141 F.T.C. 247, 283 (2006)
(Analysis of Agreement Containing Consent Order to Aid Public
Comment).
---------------------------------------------------------------------------
III. The Proposed Consent Order
The Proposed Order contains the following substantive provisions:
Section II, Paragraph A of the Proposed Order enjoins OLI from
entering or attempting to enter any agreement to refuse to publish
legal notices or allocate customers for the publication of legal
notices.
Section II, Paragraph B prohibits OLI from publically or privately
communicating with a competitor that the competitor should advice
customers to place foreclosure notices in the newspaper with the widest
circulation in the area in which the property is located, or refuse to
publish notices for properties located in a competitor's primary
distribution area.
Section II, Paragraph C, contains three provisos. The first allows
OLI to communicate with any governmental body regarding the proper
interpretation of state law related to legal notices. The second allows
OLI to participate with any effort of the Oregon newspaper association
to lobby any governmental body regarding legal notices. The third
allows OLI to disseminate information regarding legal notices to the
public.
Sections III-VI of the Proposed Order impose certain standard
reporting and compliance requirements on OLI.
The Proposed Order will expire in 10 years.
[[Page 11532]]
The purpose of this analysis is to facilitate public comment on the
proposed Consent agreement, and the Commission does not intend this
analysis to constitute an official interpretation of the proposed
Consent Agreement or to modify its terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018-05252 Filed 3-14-18; 8:45 am]
BILLING CODE 6750-01-P